openPR Logo
Press release

Market Alert: Dr. Reddy's Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression

10-10-2024 05:54 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Market Alert: Dr. Reddy's Labs Reports New Data for Aurigene

The Bottom Line:

* Aurigene Oncology, a subsidiary of Dr. Reddy's Laboratories (NSE: DRREDDY, NYSE: RDY), recently reported promising Phase 1 data for its novel CAR-T therapy, Ribrecabtagene autoleucel (DRL-1801), targeting relapsed/refractory multiple myeloma.
* All eight patients in the trial showed a 100% clinical response, with 62.5% achieving stringent complete remission.
* Notably, there were no severe adverse effects such as high-grade Cytokine Release Syndrome (CRS) or neurotoxicity.
* Following these results, India's drug regulator, DCGI, has approved the progression to Phase 2 trials.

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories (NYSE: RDY) (BSE: DRREDDY), has reported [https://finance.yahoo.com/news/aurigene-oncology-limited-announces-promising-153200321.html] positive Phase 1 results for Ribrecabtagene autoleucel (DRL-1801), India's first autologous CAR-T cell therapy targeting multiple myeloma. This breakthrough represents a significant leap in cancer treatment in India, as it offers new hope for patients with relapsed or refractory multiple myeloma-a form of cancer known to be difficult to treat after multiple rounds of therapy.

The Phase 1 trial, known as the SWASTH study, included eight heavily pre-treated patients who had undergone multiple previous lines of therapy, with a median of 5.5 prior treatments. Despite their challenging medical histories, the results were highly promising: 100% of the patients achieved a clinical response, with five out of eight (62.5%) achieving a stringent complete response, meaning no detectable traces of cancer cells post-treatment.

This is a remarkable achievement, as the stringent complete response rate is a key measure of the treatment's efficacy. Not only did the patients respond to the therapy, but the trial also demonstrated a strong safety profile. One of the most common risks associated with CAR-T cell therapies is the onset of Cytokine Release Syndrome (CRS) or neurotoxicity, both of which can be severe and life-threatening. However, none of the patients in this trial experienced high-grade CRS or neurotoxicity, a significant marker of the therapy's tolerability.

Following the success of Phase 1, the Drugs Controller General of India (DCGI) has granted approval for the trial to move into Phase 2. This will allow Aurigene to expand the trial and assess the therapy's effectiveness on a larger patient population. The results of this early-stage study were presented at the 21st Annual Meeting of the International Myeloma Society in Rio de Janeiro, garnering international recognition for this pioneering treatment.

Strategic Importance for Dr. Reddy's

This CAR-T cell therapy development marks a crucial moment in Dr. Reddy's broader strategy to expand its footprint in oncology and advanced biologics. Traditionally known for its leadership in the generics market, Dr. Reddy's has made significant strides in building its portfolio of innovative therapies, including biosimilars and now CAR-T cell treatments.

In its most recent financial results for Q1FY25, Dr. Reddy's reported consolidated revenues of 7,673 crore (US$921 million), reflecting the company's strong performance across key markets, including North America and India. The company's ongoing efforts to diversify into high-value segments like oncology, biosimilars, and consumer healthcare are part of a long-term strategy to deliver sustainable growth and value to shareholders.

Advancing Cancer Treatment in India

Dr. Murali Ramachandra, CEO of Aurigene Oncology, expressed optimism about the results, noting that this breakthrough could be transformative for Indian patients who currently have limited access to cutting-edge cancer treatments. As India's first autologous CAR-T therapy, Ribrecabtagene autoleucel represents a milestone in the country's ability to develop and deliver advanced biotechnological solutions.

The company's ability to conduct this trial in India is significant, as CAR-T therapies have historically been prohibitively expensive and largely available only in markets like the U.S. and Europe. By developing this therapy domestically, Dr. Reddy's and Aurigene are setting the stage for broader access to life-saving cancer treatments within the Indian healthcare system.

Complementing Dr. Reddy's Broader Strategic Moves

This breakthrough in CAR-T therapy complements Dr. Reddy's broader initiatives across the healthcare sector. The company has been steadily expanding its biosimilars portfolio, with key partnerships like the one with Alvotech to commercialize biosimilar denosumab in the U.S. and Europe. Additionally, Dr. Reddy's acquisition of the Nicotinell Registered brand and its joint venture with Nestle India to bring nutraceutical products to market reflect the company's growing presence in consumer healthcare and wellness.

Dr. Reddy's is also leveraging its strong financial position-highlighted by a cash surplus of 6,731 crore (US$808 million)-to invest in future growth areas. The company's focus on high-growth therapeutic areas like biosimilars and oncology, alongside its established generics business, positions it well for long-term value creation.

Looking Ahead

With the approval to move to Phase 2, Aurigene's Ribrecabtagene autoleucel is on track to potentially become a groundbreaking treatment for multiple myeloma patients in India and potentially other markets. This achievement underscores Dr. Reddy's ability to innovate in advanced therapies and aligns with its strategy to develop high-impact, cutting-edge treatments.

As Aurigene progresses through the next stages of clinical trials, investors and healthcare professionals alike will be closely watching for further data. If subsequent trials continue to show the same level of efficacy and safety, Ribrecabtagene autoleucel could become a pivotal treatment in the oncology space, not only transforming cancer care in India but also elevating Dr. Reddy's standing as a global leader in innovative pharmaceutical solutions.

Image: https://www.abnewswire.com/uploads/54d84bfd56b62b0bdc59e0df96903ebf.png

This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation [https://justpaste.it/fabrg/pdf] detailing financial compensation disclosures and disclaimers the article is subject to. The Author, Global Markets News Network, is a commercial ly operated digital brand compensated to provide coverage of news and developments innovative companies including the one aforementioned as detailed in the full documentation and it is thus subject to conflicts of interest. This article may include forward looking statements which cannot be guaranteed as discussed in the documentation. [ https://justpaste.it/fabrg/pdf ]

Media Contact
Company Name: Global Markets News Network
Contact Person: Editorial Desk
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=market-alert-dr-reddys-labs-reports-new-data-for-aurigene-cart-phase-1-gets-approvals-for-phase-2-trials-progression]
Country: India
Website: https://www.futuremarketsresearch.com/global-markets-news



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Market Alert: Dr. Reddy's Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression here

News-ID: 3685698 • Views:

More Releases from ABNewswire

Sylvie Lariviere-Traub Releases Her New Memoir - The Silent Echo of My Childhood
Sylvie Lariviere-Traub Releases Her New Memoir - The Silent Echo of My Childhood
A Powerful Story of Survival and Triumph - From Foster Homes and Juvenile Institutions to Business Success Sylvie Lariviere-Traub is pleased to announce the release of her deeply personal memoir, The Silent Echo of My Childhood, an extraordinary account of overcoming adversity, finding resilience, and achieving success against all odds. This gripping memoir takes readers on an emotional journey through Sylvie's turbulent upbringing in the Canadian foster care system and her
WebsiteDesign Promise Announces Achieving A Milestone of Two Decades in SEO Mastery
WebsiteDesign Promise Announces Achieving A Milestone of Two Decades in SEO Mast …
WebSiteDesign Promise marks its 20th anniversary today, highlighting its journey as an SEO and web design leader. Founded in 2005 by Natasa Mezej, the company has consistently provided innovative solutions tailored to the evolving needs of global markets. As it celebrates this milestone, the company is rolling out an expanded suite of services and initiating a series of educational webinars and workshops to empower business owners with practical digital marketing
B2C B2B Travel Portal System with Flights, Hotels, Transfers, Holidays CMS - Travelomatix
B2C B2B Travel Portal System with Flights, Hotels, Transfers, Holidays CMS - Tra …
Travelomatix is a next generation travel booking software platform for travel agencies and tour operators. It offers B2C, B2B and back office system with flights, hotels, transfers, car rental and holiday packages modules. Travelomatix is a leading travel portal development company [https://www.travelomatix.com/] and it develops custom booking platform to streamline and automate various tasks involved in running a travel agency. It enables agencies / users to search, compare, and book various
Postoperative Pain Pipeline Insights and Analysis 2024: FDA Approvals and Market Developments MOA, ROA by DelveInsight | Allay Therapeutics, SiteOne Therapeutics, LipoCure, Flexion Therapeutics
Postoperative Pain Pipeline Insights and Analysis 2024: FDA Approvals and Market …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Postoperative Pain pipeline constitutes 45+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Postoperative Pain Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Postoperative Pain Market. The Postoperative Pain Pipeline report

All 5 Releases


More Releases for Reddy

Finasteride market to expand US$130 million by 2026 | Key Players are Merck, Nov …
Growing awareness pertaining to prostate cancer and increased focus of men in fixing receding hair lines is poised to drive finasteride market growth. The drug specifically functions by reducing natural body hormone, which is known as DHT, which is the key factor responsible for prostate enlargement. The controlling of DHT aids in preventing prostate from growing larger, and further mitigate the risk of cancer. The drug also facilitates increased hair
Global Active Pharmaceutical Ingredients (API) Market Report 2019 Companies incl …
Market Reports Company has recently published 7th edition of Active Pharmaceutical Ingredients (API) Market Report which covers historic data of year 2013 to 2018 along with a forecast till year 2026. For inquiry or free sample pages email us at: sales@marketreportscompany.com The report provides a comprehensive view on the current state and future prospects of the market which analyzes different strategies for business growth. The global Active Pharmaceutical Ingredients (API) market was
Global Terbinafine Market 2017- Rxlist , Novartis Pharma, Dr. Reddy`s Laboratori …
The Global Terbinafine Market 2017 examines the performance of the Terbinafine market, enclosing an in-depth judgment of the Terbinafine market state and the competitive landscape globally. This report analyzes the potential of Terbinafine market in the present as well as the future prospects from various angles in detail. The Global Terbinafine Market 2017 report includes Terbinafine industry volume, market Share, market Trends, Terbinafine Growth aspects, a wide range of applications, Utilization
Global Biosimilar Monoclonal Antibodies Market 2017- Celltrion , Boehringer Inge …
The Global Biosimilar Monoclonal Antibodies Market 2017 examines the performance of the Biosimilar Monoclonal Antibodies market, enclosing an in-depth judgment of the Biosimilar Monoclonal Antibodies market state and the competitive landscape globally. This report analyzes the potential of Biosimilar Monoclonal Antibodies market in the present as well as the future prospects from various angles in detail. The Global Biosimilar Monoclonal Antibodies Market 2017 report includes Biosimilar Monoclonal Antibodies industry volume, market
Chandrashekhar Reddy, Chairman – Membership Committee of HL7 India Org joins B …
Binary Spectrum proudly announces the appointment of Chandrashekhar Reddy, Chairman of Membership Committee at HL7 India Org as Head Product Management for US products. Chandrashekhar Reddy currently holds the Chair, Membership Committee (April 2011- March 2013) under the governance structure of HL7 India Officer Elections. He has been instrumental in the accomplishment of multifaceted solutions with major involvement in decision making, presentation, negotiating, problem solving, relationship and team building. With
Shobha De to launch Leadstart Publishing’s latest book ‘P.T.O’, by Y. Sid …
Mumbai, 6th December, 2010: Eminent author and columnist Shobha De will launch, ‘P.T.O’, A Book Comprising 100 Inspiring and Humorous Quotes at Gallery BMB,Mumbai. The book is Siddharth Reddy’s debut book and a unique effort. The book has already been applauded by several dignitaries and media about its refreshing look at life. About the book: The author began writing this book in hope to remind us, as we